{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "AMRX",
  "name": "Amneal Pharmaceuticals, Inc.",
  "url": "https://frontierpicks.com/dossiers/AMRX/",
  "json_url": "https://frontierpicks.com/dossiers/AMRX.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Legacy-generics-to-specialty re-rate with both 2026 tests cleared — 2026-07-30 Q2 beat plus a second FY2026 raise, Kashiv closed 2026-08-10 on $350M of term loan and 28.9M Class A shares — but the tape has faded to a 2026-08-21 close of $17.91 with RSI(14) 39.6 and nothing hard-dated until the ~2026-11-05 (est.) Q3 print. Narrative is maturing, not accelerating.",
  "invalidation_trigger": "A weekly close below $16.50 puts price back inside the pre-print range and unwinds the post-Q2 advance; secondary break is a Q3 print (~2026-11-05, est.) that cuts the raised FY2026 guide of $3.10–3.20B revenue / $750–780M adjusted EBITDA, or post-Kashiv net leverage printing well above the 3.6x recorded at 2026-06-30.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "cyclical-industrials"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Up-C structure: Class A and Class B common stock outstanding; the 2026-08-10 Kashiv consideration was 28,942,098 Class A shares, so voting control sits outside the Class A float.",
    "Kashiv was a related party: Amneal filings disclose executive officers beneficially owning Kashiv equity and serving on its Board of Managers; a Committee of Independent Directors ran diligence.",
    "Law-firm investigation notices (Kaskela Law, 2026-07-23 and 2026-08-19) are solicitation releases; neither identifies a filed complaint against the company.",
    "Net leverage was 3.6x on TTM adjusted EBITDA of $743M at 2026-06-30, before the $350M incremental term loan drawn for the Kashiv close.",
    "AvKARE is a lower-margin distribution segment (-4% YoY in Q2 2026) and dilutes group margin whenever it outgrows Specialty.",
    "Analyst coverage is thin — four-analyst aggregator panels average roughly $17.25-$17.33 while UBS sits at $25; that sample is too small to treat as a consensus."
  ],
  "body_markdown": "\n_Refresh of coverage first published 2026-06-14; last updated 2026-08-15. Prices referenced are split/dividend-adjusted daily closes through 2026-08-21._\n\n## AMRX — Amneal Pharmaceuticals, Inc.\n\n## Current Thesis\nThe leg on offer is the same one as in June: a commodity-generics manufacturer being repriced toward a specialty-and-biosimilar multiple. Both of the scheduled tests that were pending in the prior note have now cleared. The 2026-07-30 Q2 print delivered net revenue $796M (+10% YoY from $725M), adjusted EBITDA $206M (+12%), adjusted diluted EPS $0.30 against $0.25, GAAP net income $58M against $22M, and a second FY2026 guidance raise — revenue $3.10–3.20B, adjusted EBITDA $750–780M, adjusted EPS $0.96–1.06. The Kashiv BioSciences acquisition closed 2026-08-10, financed with a $350M incremental term loan under an amended credit agreement plus 28,942,098 Class A shares.\n\nWhat has changed since the last update is the tape and the newsflow around it, not the fundamentals. The 2026-08-21 close was $17.91 against $18.15 on 2026-08-14, RSI(14) fell from 50.5 to 39.6 over the same week, and price sits 6.2% under the 52-week high of $19.10 set on the print session. The three-month price change is +44.2%. The only fresh headlines in the intervening three weeks were law-firm solicitation releases: Kaskela Law LLC published an AMRX investigation notice on Businesswire on 2026-07-23 and a second one carried by Business Wire on 2026-08-19, both saying the firm is examining whether officers or directors breached fiduciary duties or securities laws \"in connection with recent corporate actions.\" No complaint is identified in either release.\n\nThe narrative is **maturing**. Dating it — the event that carried the re-rate is behind the market (2026-07-30), the acquisition that defined the next leg has closed (2026-08-10), no confirmed company event falls between 2026-08-23 and 2026-09-22, and momentum has decayed measurably (RSI 76.9 when Benzinga screened the name on 2026-06-15, 50.5 on 2026-08-14, 39.6 on 2026-08-21). The story still works — price is within 6.2% of the high after a 44.2% three-month move — but the incremental bid has to wait for November.\n\n## Bull Case\n- Q2 2026, reported 2026-07-30: net revenue $796M (+10% YoY), adjusted EBITDA $206M (+12%), adjusted diluted EPS $0.30 vs $0.25 prior year, GAAP diluted EPS $0.18 vs $0.07. Adjusted EPS beat the roughly $0.23 consensus reported by TipRanks/TheFly.\n- Mix moved toward the higher-margin end: Specialty +17% YoY on CREXONT, BREKIYA and UNITHROID; Affordable Medicines +13% on complex generics and new launches (2026-07-30 release).\n- FY2026 guidance raised for the second time this year on 2026-07-30 — to revenue $3.10–3.20B from $3.05–3.15B, adjusted EBITDA $750–780M from $740–770M, operating cash flow $350–400M — after a guide that was merely reaffirmed at the 2026-05-07 Q1 report.\n- Kashiv closed 2026-08-10, converting a licensing relationship into an owned biosimilars platform spanning R&D, manufacturing and commercialisation. Announced terms (2026-04-21): $375M cash plus $375M equity at close, up to $350M in regulatory milestones.\n- Interest cost is falling: the July 2026 refinancing cut the Term Loan B rate 50bp, taking blended cost of debt to roughly 6% from roughly 10% in 2024, about $12M a year (2026-07-30 release).\n- Approval cadence keeps adding SKUs without clinical risk: iohexol additional strengths and vial presentations approved 2026-07-17 for Q3 2026 launch; romidepsin approved 2026-06-04 with 180-day CGT exclusivity; CHMP positive opinion for Hopledo (CREXONT in the EU, with Zambon) on 2026-06-29, launch guided from October 2026.\n- UBS raised its target to $25 from $23 on 2026-08-03 (Buy), having moved to $23 from $19 on 2026-07-15. Goldman Sachs was reported at $21 from $19 in July 2026.\n\n## Bear Case\n- Nothing is dated inside the next 30 days. The binary that produced the +15.9% session on 2026-07-30 is spent, and the next scheduled test is the Q3 print, which has historically landed in early November.\n- Leverage and dilution landed together. Net debt was $2.66B at 2026-06-30 with net leverage 3.6x on TTM adjusted EBITDA of $743M — before the $350M incremental term loan and 28,942,098 Class A shares that funded the 2026-08-10 close. The EBITDA that services both arrives one quarter later than the cost.\n- Kashiv was a related-party transaction: Amneal's SEC filings disclose that certain executive officers beneficially own Kashiv equity and serve on its Board of Managers, which is why a Committee of Independent Directors ran diligence and the deal required a shareholder vote. That governance profile is what the 2026-07-23 and 2026-08-19 Kaskela releases point at. Solicitation notices are not filed litigation, but they are a standing overhang on a controlled Up-C structure.\n- Sell-side headroom depends on which panel is read. Aggregator samples retrieved 2026-08-23 show a four-analyst average 12-month target of $17.25 (high $19, low $16), and WallStreetZen publishes $17.33 — both at or below the 2026-08-21 close of $17.91 — against UBS at $25 and Goldman at $21. Four estimates is too small a sample to call a consensus in either direction, which is itself the problem: one downgrade removes most of the visible headroom.\n- Time-boxed revenue: romidepsin's CGT exclusivity started 2026-06-04 and lapses around 2026-12-01; iohexol carries no exclusivity. Q4 sequential comparisons in Affordable Medicines will show how much of the +13% depended on the window.\n- AvKARE fell 4% YoY in Q2 2026 on lower-margin distribution pressure. A second consecutive decline would leave group growth carried by Specialty alone.\n- ADL-018, the proposed omalizumab (Xolair) biosimilar and the largest single asset the Kashiv price was set against, has had an aBLA pending since FDA acceptance in September 2025 with no publicly disclosed action date.\n\n## Setup & Price Structure\nThe 2026-07-30 session gapped the stock 15.9% to a $19.10 high; the two weeks since have been a controlled give-back rather than a break — $18.15 on 2026-08-14, $17.91 on 2026-08-21, a drawdown of 6.2% from the high. The three-month price change of +44.2% means the reference point from late May sits far below spot, so the structure that matters is the shelf the print gap left behind, in the $16.50 area, which marks the top of the pre-print range. That level has not been retested.\n\nMomentum, measured: RSI(14) at 39.6 on 2026-08-21 is the lowest reading in the covered window and a full 37 points below the 76.9 that put AMRX on Benzinga's 2026-06-15 \"may collapse this quarter\" overbought screen alongside CAH and TGTX. Price fell only 1.3% week-on-week over the same stretch — the oscillator decayed faster than the tape did.\n\nPositioning observables, stated without a verdict: (1) share supply was created into strength — 28,942,098 Class A shares issued on 2026-08-10, within roughly 6% of the 52-week high, alongside $350M of new term debt; (2) retail-facing coverage has clustered around the name twice this quarter in opposite directions, the 2026-06-15 overbought screen and the post-print beat write-ups of 2026-07-30; (3) there is no imminent earnings date to hold the bid — the next print is roughly ten weeks out; (4) no insider Form 4 activity is cited in the record reviewed for this note, so nothing is claimed about insider flow either way; (5) the Up-C structure keeps voting control concentrated in Class B, so the Class A float absorbs the issuance without a corresponding governance shift.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-23 to 2026-09-22: no confirmed company event.** No earnings, no disclosed FDA action date, no scheduled shareholder meeting is on the public record for this window. Anything that lands here arrives unscheduled — an FDA approval, an 8-K, or an ADL-018 decision.\n- **~2026-11-05 (est.)** — Q3 2026 results, the first quarter consolidating Kashiv. Resolves post-deal net leverage against the 3.6x at 2026-06-30, the diluted share count after the 28,942,098-share issuance, and whether the $3.10–3.20B FY2026 guide holds with one quarter left.\n- **~2026-12-01 (est.)** — romidepsin 180-day CGT exclusivity window closes (clock started 2026-06-04).\n- **Undated — aBLA accepted September 2025** — FDA decision on ADL-018 (omalizumab biosimilar). No public action date; the outcome can land in either direction without warning.\n\n## Elapsed catalysts\n\n- **~2026-10 (est.)** — Hopledo (CREXONT EU brand, Zambon partnership) launch, guided from October 2026 following the 2026-06-29 CHMP positive opinion. First EU revenue from the highest-margin specialty asset. *(passed 58d ago)*\n\n## What Would Change Our Mind\nThe structure to watch is the pre-print shelf, not the 52-week high. Price has held above roughly $16.50 since the 2026-07-30 gap; a weekly close below $16.50 would put the stock back inside the range it occupied before the beat and the raise, which would say the market has stopped paying for the second guidance raise and the closed acquisition together. That is the gradeable break.\n\nThree non-price conditions would do the same work more slowly. First, a Q3 print around 2026-11-05 (est.) that trims the raised FY2026 guide of $3.10–3.20B revenue / $750–780M adjusted EBITDA, or that shows post-Kashiv net leverage materially above the 3.6x recorded at 2026-06-30 with no stated deleveraging path — the deal was underwritten on EBITDA arriving faster than the debt and the shares. Second, an 8-K or release disclosing a Complete Response Letter, a resubmission, or an FDA information request on the ADL-018 aBLA, which would defer the biosimilar revenue the Kashiv price assumed. Third, the Kaskela releases of 2026-07-23 and 2026-08-19 converting into a filed complaint or a books-and-records demand naming the Kashiv process — a solicitation notice carries no information; a filed pleading with specifics would.\n\nThe reverse case: Specialty holding a growth rate in the high teens at the Q3 print with AvKARE stabilising, plus Hopledo shipping in Q4, would extend the re-rate rather than end it. On the current record neither branch resolves before November.\n\n## Correlation Notes\n- Sector beta is a weak explanation here. The dated moves in this name — 2026-06-04 romidepsin approval, 2026-07-17 iohexol strengths, the 2026-07-30 print, the 2026-08-10 close — are company-specific approvals and financing events. That is an inference from the event dates, not a measured beta.\n- The generic-pricing complex (Teva, Viatris, Organon and the Indian exporters) shares AMRX's exposure to US price erosion and to any tariff schedule naming generic pharmaceutical imports. Amneal's India-and-US manufacturing footprint sits directly in that policy path; management has not publicly quantified a tariff cost for FY2027.\n- The biosimilar leg correlates with FDA interchangeability and reimbursement policy rather than with biotech risk appetite; XBI/IBB moves are a poor read-across for a company whose biosimilar value rests on a pending aBLA and existing filgrastim/pegfilgrastim commercialisation.\n- Rate sensitivity is real but shrinking: blended cost of debt near 6% after the July 2026 refinancing, versus roughly 10% in 2024, against $2.66B of net debt at 2026-06-30. Further Term Loan B repricing is a lever that does not need a product to work.",
  "first_seen": "2026-06-14",
  "last_analyzed": "2026-08-23T12:03:52+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}